Capricor Therapeutics, Inc. (CAPR) on Wednesday announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel for the treatment of Duchenne muscular dystrophy (DMD). The study met its primary endpoint, sending the company's shares up more than 14% in pre-market trading.
The trial randomized participants to receive either Deramiocel or a placebo over a 12-month period. Results showed clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential first-in-class therapy targeting Duchenne cardiomyopathy, the leading cause of mortality in DMD. The therapy maintained a favorable safety and tolerability profile, consistent with previous clinical experience.
Capricor plans to submit its response to the Complete Response Letter for Deramiocel's Biologics License Application (BLA) received in July, incorporating the HOPE-3 data, following prior alignment with the U.S. Food and Drug Administration.
Capricor Therapeutics shares had closed at $6.36, down 4.36% on Tuesday.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.